TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial

Lorraine B. Ware(Vanderbilt University Medical Center), Tobias Welte(Medizinische Hochschule Hannover), Nima Soleymanlou(Boehringer Ingelheim (Canada)), Peter LaCamera(Harvard University), Abhya Gupta(Boehringer Ingelheim (Germany)), Vicente Estrada(Instituto de Salud Carlos III), George A. Diaz(Providence Regional Medical Center Everett), Wansuk Choi(Boehringer Ingelheim (United States))

Thorax

April 6, 2023

10.1136/thorax-2022-219668

Cited by 9

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy

|JAMA|2016|1.4k

Clinical and economic burden of community-acquired pneumonia among adults in Europe

|Thorax|2010|1.1k

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

|The Lancet|2019|1k

Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study

|The Lancet Respiratory Medicine|2020|864

The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak

|Nature Medicine|2007|820